Showing results (31-40 of 129) with videos related to
Sort By:
Pageof 13
Cancer Research|May 23, 2002
A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cellsMatthias Peipp, Heide Küpers, Domenica Saul, et al.Frontiers in Immunology|January 8, 2015
Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based ImmunotherapyHans-Heinrich Oberg, Christian Kellner, Matthias Peipp, et al.Plos One|August 11, 2012
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96Sahar Mohseni Nodehi, Roland Repp, Christian Kellner, et al.Frontiers in Immunology|May 5, 2018
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer CellsHans H Oberg, Christian Kellner, Daniel Gonnermann, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptorMichael Dechant, Thomas Beyer, Tanja Schneider-Merck, et al.Oncotarget|November 5, 2017
A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display librariesKatja Klausz, Michael Cieker, Christian Kellner, et al.Methods in Molecular Biology (Clifton, N.J.)|July 5, 2023
Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface DisplayStefan Zielonka, Simon Krah, Paul Arras, et al.Frontiers in Immunology|December 16, 2020
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark AntibodiesArturo Macarrón Palacios, Julius Grzeschik, Lukas Deweid, et al.Frontiers in Immunology|September 27, 2019
TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer CellsDoaa Tawfik, Christopher Groth, Jan-Paul Gundlach, et al.Frontiers in Immunology|August 4, 2025
Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancerHans-Heinrich Oberg, Malte Deseke, Steffen Krohn, et al.Pageof 13